Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Exclusion Criteria

• •No known brain metastases
• •Performance status - GOG 0-1
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• •SGOT ≤ 2.5 times ULN
• •Alkaline phosphatase ≤ 2.5 times ULN
• •Creatinine ≤ 1.5 times ULN
• •No symptomatic congestive heart failure
• •No unstable angina pectoris
• •No cardiac arrhythmia
• •Able to take oral medication
• •No bowel obstruction
• •No persistent vomiting
• •No parenteral feeding
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for ≥ 1 month after completion of study treatment
• •No neuropathy (sensory and motor) \> grade 1
• •No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• •No active infection requiring antibiotics
• •No psychiatric illness or social situation that would preclude study compliance
• •No history of allergic reaction attributed to compounds of similar chemical or biological composition to vorinostat
• •No other uncontrolled illness
• •At least 4 weeks since prior immunotherapy for the malignancy
• •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) for the malignancy and recovered
• •No more than 2 prior cytotoxic chemotherapy regimens for recurrent or persistent disease
• •No prior non-cytotoxic chemotherapy for recurrent or persistent disease, unless therapy was part of the primary treatment regimen
• •No prior vorinostat
• •At least 1 week since prior hormonal therapy for the malignancy
• •Concurrent hormone replacement therapy allowed
• •At least 4 weeks since prior radiotherapy for the malignancy and recovered
• •No prior radiotherapy to \> 25% of bone marrow
• •At least 4 weeks since prior surgery for the malignancy and recovered
• •At least 4 weeks since other prior therapy for the malignancy
• •At least 30 days since prior and no concurrent valproic acid
• •Concurrent oral anticoagulants (i.e., warfarin) allowed provided there is increased vigilance with respect to monitoring PT/INR for the first 2 courses of study therapy or if there are any signs of bleeding
• •No prior anticancer therapy that would preclude study participation
• •No concurrent combination anti-retroviral therapy for HIV-positive patients
• •No other concurrent investigational agents